$1.08
-0.03[-2.70%]
At close: Apr 18
$1.08
0[0.00%]
After Hours: 7:54PM EDT
Rigel Pharmaceuticals
(NASDAQ:RIGL)Rigel Pharmaceuticals Stock (NASDAQ:RIGL), Analyst Ratings, Price Targets, Predictions
Rigel Pharmaceuticals Inc has a consensus price target of $4.32, established from looking at the 22 latest analyst ratings. The last 3 analyst ratings were released from Citigroup, Cantor Fitzgerald, and HC Wainwright & Co. on March 7, 2024, March 6, 2024, and March 6, 2024. With an average price target of $7.33 between Citigroup, Cantor Fitzgerald, and HC Wainwright & Co., there's an implied 579.01% upside for Rigel Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Citigroup
Cantor Fitzgerald
HC Wainwright & Co.
B. Riley Securities
Piper Sandler
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Rigel Pharmaceuticals
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/07/2024 | RIGL | Buy Now | Rigel Pharmaceuticals | $1.08 | 270.37% | Citigroup | Yigal Nochomovitz | $3 → $4 | Maintains | Buy | Get Alert |
| 03/06/2024 | RIGL | Buy Now | Rigel Pharmaceuticals | $1.08 | 177.78% | Cantor Fitzgerald | Kristen Kluska | $2 → $3 | Maintains | Neutral | Get Alert |
| 03/06/2024 | RIGL | Buy Now | Rigel Pharmaceuticals | $1.08 | 1288.89% | HC Wainwright & Co. | Joseph Pantginis | → $15 | Reiterates | Buy → Buy | Get Alert |
| 03/06/2024 | RIGL | Buy Now | Rigel Pharmaceuticals | $1.08 | 15.74% | B. Riley Securities | Kalpit Patel | $1.25 → $1.25 | Maintains | Neutral | Get Alert |
| 02/22/2024 | RIGL | Buy Now | Rigel Pharmaceuticals | $1.08 | 1288.89% | HC Wainwright & Co. | Joseph Pantginis | → $15 | Reiterates | Buy → Buy | Get Alert |
| 01/04/2024 | RIGL | Buy Now | Rigel Pharmaceuticals | $1.08 | 1288.89% | HC Wainwright & Co. | Joseph Pantginis | → $15 | Reiterates | Buy → Buy | Get Alert |
| 12/08/2023 | RIGL | Buy Now | Rigel Pharmaceuticals | $1.08 | 1288.89% | HC Wainwright & Co. | Joseph Pantginis | → $15 | Reiterates | Buy → Buy | Get Alert |
| 08/02/2023 | RIGL | Buy Now | Rigel Pharmaceuticals | $1.08 | 1288.89% | HC Wainwright & Co. | Joseph Pantginis | → $15 | Reiterates | Buy → Buy | Get Alert |
| 05/03/2023 | RIGL | Buy Now | Rigel Pharmaceuticals | $1.08 | 1288.89% | HC Wainwright & Co. | Joseph Pantginis | → $15 | Reiterates | → Buy | Get Alert |
| 04/03/2023 | RIGL | Buy Now | Rigel Pharmaceuticals | $1.08 | 85.19% | Piper Sandler | Allison Bratzel | → $2 | Assumes | → Neutral | Get Alert |
| 03/09/2023 | RIGL | Buy Now | Rigel Pharmaceuticals | $1.08 | 177.78% | Citigroup | Yigal Nochomovitz | $2 → $3 | Maintains | Buy | Get Alert |
| 03/08/2023 | RIGL | Buy Now | Rigel Pharmaceuticals | $1.08 | 1288.89% | HC Wainwright & Co. | Joseph Pantginis | → $15 | Reiterates | → Buy | Get Alert |
| 12/02/2022 | RIGL | Buy Now | Rigel Pharmaceuticals | $1.08 | — | Citigroup | Yigal Nochomovitz | — | Upgrade | Neutral → Buy | Get Alert |
| 11/04/2022 | RIGL | Buy Now | Rigel Pharmaceuticals | $1.08 | 177.78% | BMO Capital | Gary Nachman | $4 → $3 | Maintains | Outperform | Get Alert |
| 08/18/2022 | RIGL | Buy Now | Rigel Pharmaceuticals | $1.08 | 1288.89% | HC Wainwright & Co. | Joseph Pantginis | $7 → $15 | Maintains | Buy | Get Alert |
| 08/17/2022 | RIGL | Buy Now | Rigel Pharmaceuticals | $1.08 | 85.19% | Piper Sandler | Do Kim | $1 → $2 | Maintains | Neutral | Get Alert |
| 06/09/2022 | RIGL | Buy Now | Rigel Pharmaceuticals | $1.08 | 177.78% | BMO Capital | Gary Nachman | $7 → $3 | Maintains | Outperform | Get Alert |
| 06/09/2022 | RIGL | Buy Now | Rigel Pharmaceuticals | $1.08 | 15.74% | B. Riley Securities | Kalpit Patel | $4 → $1.25 | Maintains | Neutral | Get Alert |
| 06/09/2022 | RIGL | Buy Now | Rigel Pharmaceuticals | $1.08 | -25.93% | Citigroup | Yigal Nochomovitz | $7 → $0.8 | Downgrade | Buy → Neutral | Get Alert |
FAQ
What is the target price for Rigel Pharmaceuticals (RIGL)?
The latest price target for Rigel Pharmaceuticals (NASDAQ: RIGL) was reported by Citigroup on March 7, 2024. The analyst firm set a price target for $4.00 expecting RIGL to rise to within 12 months (a possible 270.37% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Rigel Pharmaceuticals (RIGL)?
The latest analyst rating for Rigel Pharmaceuticals (NASDAQ: RIGL) was provided by Citigroup, and Rigel Pharmaceuticals maintained their buy rating.
When was the last upgrade for Rigel Pharmaceuticals (RIGL)?
The last upgrade for Rigel Pharmaceuticals Inc happened on December 2, 2022 when Citigroup raised their price target to N/A. Citigroup previously had a neutral for Rigel Pharmaceuticals Inc.
When was the last downgrade for Rigel Pharmaceuticals (RIGL)?
The last downgrade for Rigel Pharmaceuticals Inc happened on June 9, 2022 when Citigroup changed their price target from $7 to $0.8 for Rigel Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Rigel Pharmaceuticals (RIGL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rigel Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rigel Pharmaceuticals was filed on March 7, 2024 so you should expect the next rating to be made available sometime around March 7, 2025.
Is the Analyst Rating Rigel Pharmaceuticals (RIGL) correct?
While ratings are subjective and will change, the latest Rigel Pharmaceuticals (RIGL) rating was a maintained with a price target of $3.00 to $4.00. The current price Rigel Pharmaceuticals (RIGL) is trading at is $1.08, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.